madman
Super Moderator
This video discusses the use of gonadotropin therapy in male infants and adolescents with hypogonadism. Dr. Sasha Howard from Queen Mary University of London explains the evidence and best practices for this treatment. She emphasizes the importance of early diagnosis and treatment to improve patient outcomes and fertility.
2023 Anne Klibanski Visiting Lecture Series 08 with Dr. Sasha Howard
- Dr. Sasha Howard discusses the use of gonadotropin therapy in males with hypogonadism.
- The Ann Klibanski Visiting Scholar Award is an opportunity for faculty to gain recognition and expand their network.
- The lecture series fosters collaborations across national and international institutions.
- Collaborations have included institutions like Queen Mary University of London.
- The use of gonadotropin therapy in male patients with hypogonadism leads to improved testicular and penile size, serum testosterone, and spermatogenesis.
- Combination therapy with FSH and HCG appears to have better outcomes than HCG monotherapy.
- The treatment is well-tolerated with minimal adverse effects.
- Gonadotropin therapy in infancy is effective in achieving testicular volume increase, testicular descent, and improved biochemical parameters.
- Further research and data collection are needed to determine the best practices and long-term outcomes of gonadotropin therapy in both adolescence and infancy.
- The use of gonadotropin therapy should be considered in patients with severe hypogonadism who are unresponsive to testosterone treatment or desire testicular development and sperm banking.
